restor3D raised USD $4.4 million in equity, bringing its total raised to $5.4 million since 2017. The company develops 3D-printed implants, and entered into a development and licensing agreement with SeaSpine in late 2019.
restor3d’s materials science technology complements SeaSpine’s orthobiologics portfolio. They will leverage their specialties to develop interbodies for a range of surgical approaches, while driving clinical and economic advantages.
Products arising from this collaboration are slated for launch in 2H20.
restor3D raised USD $4.4 million in equity, bringing its total raised to $5.4 million since 2017. The company develops 3D-printed implants, and entered into a development and licensing agreement with SeaSpine in late 2019.
restor3D raised USD $4.4 million in equity, bringing its total raised to $5.4 million since 2017. The company develops 3D-printed implants, and entered into a development and licensing agreement with SeaSpine in late 2019.
restor3d’s materials science technology complements SeaSpine’s orthobiologics portfolio. They will leverage their specialties to develop interbodies for a range of surgical approaches, while driving clinical and economic advantages.
Products arising from this collaboration are slated for launch in 2H20.
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
Copy to clipboard 
